# Metastatic prostate cancer

**Poster Session 29**

**Sunday 11 July**  
16:00 - 17:00

**Location**  
Virtual Room 6

**Chairs**  
N. Fossati, Milan (IT)  
B. Tombal, Brussels (BE)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

### 16:00 - 16:01  
**Introduction**  
B. Tombal, Brussels (BE)

### 16:01 - 16:15  
**Lymphnode metastases**

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P0836</td>
<td>External validation of a nomogram for predicting 68Ga-PSMA PET/CT detection rate in patients with prostate cancer recurrence. A clinical tool to guide physicians before suggesting 68Ga-PSMA PET/CT</td>
<td>L. Bianchi, Bologna (IT)</td>
</tr>
<tr>
<td>P0837</td>
<td>Diagnostic accuracy of PSMA-PET-CT for pelvic lymph node staging in men with prostate cancer undergoing radical prostatectomy and pelvic lymph node dissection</td>
<td>J.B. Grogg, Zurich (CH)</td>
</tr>
<tr>
<td>P0838</td>
<td>Lymph node staging with 18F-PSMA-1007 PET/CT in newly diagnosed prostate cancer using histopathological evaluation as a reference</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>P0839</td>
<td>Salvage Therapies for PSMA PET/CT-positive nodal-only recurrent prostate cancer: Impact on survival, functional outcomes and health-related quality of life</td>
<td>A. Kretschmer, Munich (DE)</td>
</tr>
<tr>
<td>P0840</td>
<td>Preoperative prediction of lymph node invasion in prostate cancer: Ga-68 PSMA PET or nomograms?</td>
<td>Y. Kordan, Istanbul (TR)</td>
</tr>
<tr>
<td>P0841</td>
<td>Postoperative complications and functional outcome parameters in patients undergoing salvage lymph-node dissection due to nodal-recurrent prostate cancer</td>
<td>M.T. Grabbert, Freiburg (DE)</td>
</tr>
</tbody>
</table>

### 16:07 - 16:15  
**Discussion**

### 16:15 - 16:24  
**Metastatic hormone-sensitive disease**

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P0842</td>
<td>Metastasis-directed therapy for oligorecurrent prostate cancer: A pooled analysis of prospective trials</td>
<td>P. Ost, Ghent (BE)</td>
</tr>
<tr>
<td>P0843</td>
<td>Predictors of recurrence after metastasis-directed therapy in metachronous, castrate-sensitive oligometastatic prostate cancer</td>
<td>U. Milenkovic, Leuven (BE)</td>
</tr>
</tbody>
</table>
| P0844 | Which patients with Oligometastatic Prostate Cancer should be considered for Cytoreductive Radical Prostatectomy as part of a multimodal treatment? Results from a large, multi-institutional collaboration  
S. Scuderi, Catania (IT) |
| P0845 | Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)  
S. Chowdhury, London (GB) |
| P0846 | Prognostic importance of concomitant non-regional lymph node and bone metastases in men with de novo metastatic prostate cancer  
B.L. Heesterman, Utrecht (NL) |
| P0847 | Androgen deprivation therapy and excess mortality during the COVID-19 pandemic  
P. Stattin, Uppsala (SE) |
| P0848 | Severity of COVID-19 infection in prostate cancer patients and effect of ADT on disease presentation  
C. García Fuentes, Alcorcón (ES) |
| P0849 | Adjuvant Metformin use in advanced hormone sensitive prostate cancer; Clinical assessment through a randomized trial |
| P0850 | Type of androgen deprivation therapy and the risk of cardiovascular diseases in patients with prostate cancer with or without pre-existing cardiovascular risk  
N. Touma, Laval (CA) |
| P0851 | Diabetes control in men with type 2 diabetes mellitus and prostate cancer treated with GnRH Agonists: A nationwide, population-based cohort study  
E. Lin, London (GB) |

### 16:24 - 16:32 Discussion

### 16:32 - 16:52 Castration resistant disease

| P0852 | Fatigue, quality-of-life and metabolic changes in men treated with enzalutamide versus abiraterone plus prednisone for metastatic castration-resistant prostate cancer (HEAT): A randomised trial  
K. Kvorning Ternov, Hellerup (DK) |
| P0853 | Geriatric nutritional risk index as a prognostic marker for patients with metastatic castration-resistant prostate cancer receiving docetaxel  
H. Hsieh, Taichung (TW) |
| P0854 | Distinct response to platinum-based chemotherapy among patients with metastatic castration-resistant prostate cancer harboring alterations in genes involved in homologous recombination  
L. Fan, Shanghai (CN) |
| P0855 | The obesity paradox in metastatic castration resistant prostate cancer  
G.O. Cirulli, Roma (IT) |
| P0856 | Prospective study of the relationship between clinical outcomes of enzalutamide and serum androgen levels measured by LC-MS/MS in CRPC patients  
Y. Miyazawa, Maebashi, Gunma (JP) |
| P0857 | A drug comorbidity index to predict all-cause mortality in men with castration resistant prostate cancer  
G. Fallara, Meda (IT) |
| P0858 | Serum testosterone levels and testosterone ‘bounce’ phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer  
Y.G. Tan, Singapore (SG) |
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P0859</td>
<td>Clinical study of VERU-111, an oral cytoskeletal disruptor in men with metastatic Castration Resistant Prostate Cancer (mCRPC) who failed an androgen receptor targeting agent</td>
<td>R. Getzenberg, Memphis, Tn (US)</td>
<td></td>
</tr>
<tr>
<td>P0860</td>
<td>Balancing efficacy and toxicity of docetaxel in patients with metastatic castration-resistant prostate cancer. Results from a pooled analysis of three prospective randomized trials</td>
<td>G.O. Cirulli, Roma (IT)</td>
<td></td>
</tr>
<tr>
<td>P0861</td>
<td>A multi-trial based external validation of the Halabi nomogram in predicting the overall survival of metastatic castration-resistant prostate cancer patients</td>
<td>D. Modonutti, Pagnacco (IT)</td>
<td></td>
</tr>
<tr>
<td>P0862</td>
<td>Impact of Prior Local Trecepherapy (PLT) on survival in metastatic castration resistant prostate cancer (mCRPC). Results from COU-AA-302 trial</td>
<td>M. Rodrigo-Aliaga, Benicàssim (ES)</td>
<td></td>
</tr>
<tr>
<td>P0863</td>
<td>Time on treatment with abiraterone and enzalutamide in the patient-overview prostate cancer in the national prostate cancer register of Sweden</td>
<td>G. Fallara, Meda (IT)</td>
<td></td>
</tr>
</tbody>
</table>

**16:44 - 16:52**  
**Discussion**

**16:52 - 16:57**  
**Expert summary**  
C. Ryan, Minneapolis (US)